French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Limoges

About this trial

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. Studies have shown the importance of weight loss at the time of diagnosis and during the progression of the disease. However, the pathophysiological mechanisms behind weight loss remain unknown. Identifying these mechanisms could make it possible to propose an effective therapeutic strategy against weight loss for ALS patients, which could improve their survival and quality of life. In this context, the investigators are proposing an innovative multidisciplinary project aimed at structuring a large Franco-German cohort to identify the markers associated with weight loss in ALS.

Participants will undergo high quality standard care for ALS patients. In addition, participants will be asked to respond different questionnaires and blood samples will be taken for analysis to identify biological markers.

Eligibility criteria

Qualifiers

Incident cases included at the time of diagnosis with a definite, probable, probable laboratory-supported, or possible ALS according to El Escorial revised criteria and Gold Coast criteria for early diagnosis.

Incident ALS cases identified and followed-up in the participant ALS & Other Motor Neuron Diseases Referral Centres: seven in France and two in Germany.

Patients who signed the informed consent form.

Adults aged >18 years old

Disqualifiers

Inability to understand the requirements of the protocol.

Cognitive inability to sign and comprehend the informed consent form.

Patients who will not accept Riluzole therapy during their follow-up.

Trial design

Treatments tested in this trial

  • Blood sample

Treatment groups

1,000 Participants
are divided into 1 treatment group

Sponsors and collaborators

University Hospital, Limoges

Lead sponsor

National Research Agency, France

Collaborator

Centre de Recherche en biomédecine de Strasbourg INSERM UMR-S1118

Collaborator

Paris Brain Institute (ICM)

Collaborator

Institut National de la Santé et de la Recherche Médical - délégation Grand Ouest INSERM U1253

Collaborator

Klinik für Neurologie, Universitäts- und Rehabilitationskliniken Ulm (RKU)

Collaborator

Centre de Données Cliniques et de Recherche CDCR

Collaborator

UMR Inserm U1253-IBRain-Neurogénétique et Physiopathologie Neuronale

Collaborator

France Cohorte

Collaborator